- Home
- PETS vs BDSX Comparison
PETS vs BDSX Comparison
Compare PETS & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- BDSX
- Stock Information
- Founded
- PETS 1996
- BDSX 2005
- Country
- PETS United States
- BDSX United States
- Employees
- PETS N/A
- BDSX N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- BDSX Precision Instruments
- Sector
- PETS Consumer Staples
- BDSX Health Care
- Exchange
- PETS Nasdaq
- BDSX Nasdaq
- Market Cap
- PETS 58.9M
- BDSX 53.2M
- IPO Year
- PETS N/A
- BDSX 2020
- Fundamental
- Price
- PETS $2.82
- BDSX $6.56
- Analyst Decision
- PETS Sell
- BDSX Strong Buy
- Analyst Count
- PETS 1
- BDSX 5
- Target Price
- PETS $3.20
- BDSX $35.00
- AVG Volume (30 Days)
- PETS 92.2K
- BDSX 263.0K
- Earning Date
- PETS 11-05-2025
- BDSX 10-31-2025
- Dividend Yield
- PETS N/A
- BDSX N/A
- EPS Growth
- PETS N/A
- BDSX N/A
- EPS
- PETS 0.02
- BDSX N/A
- Revenue
- PETS $247,010,000.00
- BDSX $76,556,000.00
- Revenue This Year
- PETS N/A
- BDSX $18.80
- Revenue Next Year
- PETS N/A
- BDSX $27.76
- P/E Ratio
- PETS $164.97
- BDSX N/A
- Revenue Growth
- PETS N/A
- BDSX 25.70
- 52 Week Low
- PETS $2.72
- BDSX $3.44
- 52 Week High
- PETS $6.85
- BDSX $37.00
- Technical
- Relative Strength Index (RSI)
- PETS 50.01
- BDSX 38.34
- Support Level
- PETS N/A
- BDSX $7.06
- Resistance Level
- PETS $3.08
- BDSX $10.60
- Average True Range (ATR)
- PETS 0.10
- BDSX 1.06
- MACD
- PETS -0.12
- BDSX -0.29
- Stochastic Oscillator
- PETS 88.68
- BDSX 3.64
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.